Food Allergy – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034
Food Allergy Market Outlook
Thelansis’s “Food Allergy Market
Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024
To 2034" covers disease overview, epidemiology, drug utilization,
prescription share analysis, competitive landscape, clinical practice,
regulatory landscape, patient share, market uptake, market forecast, and key
market insights under the potential Food Allergy treatment modalities options
for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and
China).
Food
Allergy Overview
Food
allergy is an immune reaction to proteins in the food and can be immunoglobulin
(Ig)E-mediated or non–IgE-mediated. Allergic reactions secondary to food
ingestion are responsible for various symptoms involving the skin,
gastrointestinal tract, and respiratory tract. Depending on the mechanism, food
allergy can have two etiology- IgE-mediated or type-I hypersensitivity and
other immunologically non-mediated reactions. The allergens are generally
water-soluble glycoproteins resistant to breakdown and easily transported
across the mucosal surface in the intestine. Risk factors for severe food
allergies include asthma, prior episode of anaphylaxis and delay in the use of
epinephrine. When a person is exposed to specific allergens, IgE antibodies
specific to food develop that bind to Fc epsilon receptors on basophils,
macrophages, mast cells, and dendritic cells. Once food allergens pass through
the mucosal barriers and reach cell-bound IgE antibodies, these mediators are
released, causing smooth muscle contraction, vasodilation, and mucus secretion,
resulting in acute hypersensitivity.
Geography
coverage:
G8 (United States,
EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)
Insights driven
by robust research, including:
- In-depth interviews with leading
KOLs and payers
- Physician surveys
- RWE analysis for claims and EHR
datasets
- Secondary research (e.g.,
peer-reviewed journal articles, third-party research databases)
Deliverables
format and updates*:
- Detailed Report (PDF)
- Market Forecast Model (MS
Excel-based automated dashboard)
- Epidemiology (MS Excel; interactive
tool)
- Executive Insights (PowerPoint
presentation)
- Others: regular updates,
customizations, consultant support
*As per
Thelansis’s policy, we ensure that we include all the recent updates before
releasing the report content and market model.
Salient
features of Market Forecast model:
- 10-year market forecast (2024–2034)
- Bottom-up patient-based market
forecasts validated through the top-down sales methodology
- Covers clinically and
commercially-relevant patient populations/ line of therapies
- Annualized drug-level sales and
patient share projections
- Utilizes our proprietary Epilansis and Analog tool
(e.g., drug uptake and erosion) datasets and conjoint analysis approach
- Detailed methodology/sources
& assumptions
- Graphical and tabular outputs
- Users can customize the model based
on requirements
Key business
questions answered:
- How can drug development and
lifecycle management strategies be optimized across G8 markets (US, EU5,
Japan, and China)?
- How large is the patient population
in terms of incidence, prevalence, segments, and those receiving drug
treatments?
- What is the 10-year market outlook
for sales and patient share?
- Which events will have the greatest
impact on the market’s trajectory?
- What insights do interviewed experts
provide on current and emerging treatments?
- Which pipeline products show the
most promise, and what is their potential for launch and future
positioning?
- What are the key unmet needs and KOL
expectations for target profiles?
- What key regulatory and payer
requirements must be met to secure drug approval and favorable market
access?
- and more…
Comments
Post a Comment